CMS grants NTAP reimbursement status for Abeona gene therapy ZEVASKYN under FY2027 IPPS rule
ABEO•CMS grants NTAP status for ZEVASKYN
- CMS granted New Technology Add-On Payment status for ZEVASKYN under the FY2027 Hospital Inpatient Prospective Payment System final rule.
- NTAP provides supplemental Medicare reimbursement above standard hospital inpatient payments, supporting access to the gene therapy in eligible cases.
- Decision strengthens Medicare reimbursement alongside ZEVASKYN’s permanent J-code, supporting coverage for Medicare patients, including those with qualifying disabilities.
